Skip to main content
October 01, 2020
Deutetrabenazine offers long-term benefit for patients with severe tardive dyskinesia (TD), according to results from a 3-year open-label extension trial presented in a poster at Psych Congress 2020.
October 01, 2020
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”
October 01, 2020
A decrease of 3 points on the Abnormal Involuntary Movement Scale score is the minimal clinically important difference for treatment of tardive dyskinesia with deutetrabenazine, according to a poster presented at Psych Congress 2020. 
VIDEO
September 23, 2020
Psych Congress 2020 presenter Timothy Wilens, MD, discusses the ways in which early treatment can improve outcomes in patients with attention-deficit/hyperactivity disorder (ADHD). 
September 14, 2020
Physician assistants (PAs) may offer an effective way to ensure patients have access to quality mental health care despite the projected shortage of psychiatrists in the near future, according to a poster presented at Psych Congress 2020.
September 13, 2020
Introducing time-limited adaptive stressors has demonstrated a profound effect on patient well-being, but efforts to sidestep stress often overshadow these approaches in today's society, Psych Congress 2020 cochair Charles Raison, MD, said at the conference.
September 13, 2020
Psych Congress 2020 speaker Joseph F. Goldberg, MD, details factors that could influence a patient's response to a treatment for bipolar disorder, and how clinicians can address them.
September 13, 2020
Psych Congress 2020 speaker Marc E. Agronin, MD, shares strategies that mental health clinicians can use to adjust psychopharmacologic treatment and dosages for geriatric patients.
September 13, 2020
A pharmacogenomic test was associated with improved outcomes in patients with major depressive disorder who failed to improve with previous antidepressant treatment, according to a meta-analysis presented at Psych Congress 2020.
September 13, 2020
A secondary analysis of a study investigating adjunctive pimavanserin for the treatment of patients with major depressive disorder found that it significantly improved insomnia and sleepiness, researchers reported at Psych Congress 2020. 
Back to Top